Baiyunshan (00874) announced interim results, net profit of about 2,096 billion yuan, a year-on-year decrease of 16.7%

According to the Zhitong Finance App, Baiyunshan (00874) announced the 2026 interim results, with operating income of about 42,091 billion yuan, up 0.61% year on year; net profit attributable to the company's shareholders was about 2,096 billion yuan, a year-on-year decrease of 16.7%; basic earnings per share were 1.289 yuan, with a cash dividend of 0.30 yuan (tax included) per share.

During the reporting period, sales revenue of products such as Angong beef yellow pills, amoxicillin series, cefixime series, children's seven star tea, and Kunxian capsules achieved the same and relatively rapid growth; national and local procurement declarations and basic drug catalogue entry arrangements were actively promoted. During the reporting period, 24 products, including injectable cefuzin sodium, clindamycin phosphate injections, memantine hydrochloride tablets, and amoxicillin granules, were successfully selected for continuous collection by the National Organization. After the reporting period, 19 new product specifications including Xiaochaihu granules entered the “National Essential Medicines Catalogue (2026 Edition)”; continued to strengthen brand building, establish a self-owned brand matrix to expand the brand's influence in the local market; and hundreds of high-quality products opened cooperation channels at the China Merchants Conference and continued to broaden the sales network.

In addition, the group expects capital expenditure of approximately RMB 2.152 billion in 2026, of which it has already spent RMB 536 million in the first half of 2026 (first half of 2025: RMB 649 million), mainly for production base construction, equipment renewal, and information system construction.